Sangamo Therapeutics agreed to sell ST-920 Assets to PTC Therapeutics for $111,000,000 in cash, plus up to $100,000,000 in milestone payments. For investors, the consideration includes $80,000,000 for accelerated FDA approval and $20,000,000 for full approval, while the transaction remains subject to Bankruptcy Court approval.

Key Highlights

  • PTC Therapeutics would pay $80,000,000 if ST-920 receives accelerated FDA approval based on the STAAR Studies.
  • A further $20,000,000 payment depends on full FDA approval for ST-920.
  • A Bankruptcy Court hearing on the transaction is scheduled for September 10, 2026.

SANGAMO THERAPEUTICS, INC (OTC: SGMOQ). Agreed to sell assets tied primarily to ST-920, its one-time administered AAV gene therapy candidate for Fabry disease, to PTC Therapeutics for $111,000,000 in cash at closing.

ST-920 Sale Includes Cash and Milestone Consideration

The asset purchase agreement covers Sangamo’s rights and interests in ST-920, also known as isaralgagene civaparvovec, along with assets primarily related to the product candidate. PTC was selected as the winning bidder at an auction before the agreement was signed on August 25, 2026.

The contingent payments include $80,000,000 after accelerated FDA approval of a Biologics license application based on the Phase 1/2 STAAR Studies and related long-term follow-up study. Another one-time payment of $20,000,000 would be payable after full FDA approval based on those studies.

The proposed sale remains subject to a Bankruptcy Court order authorizing the transaction and transferring the assets free of liens. Other closing conditions include the end of waiting periods under the HSR Act, the absence of legal restrictions, accurate representations and warranties, covenant performance, no Seller Material Adverse Effect and satisfaction of employee retention conditions.

A hearing to consider approval is scheduled for September 10, 2026. Either party may terminate the agreement if closing has not occurred by October 15, 2026, subject to specified exceptions, while PTC has additional termination rights tied to court orders and other Chapter 11 case events.

Peers Moving on This News